Concepts (188)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Small Molecule Libraries | 12 | 2025 | 129 | 3.760 |
Why?
|
| Drug Discovery | 7 | 2024 | 171 | 1.640 |
Why?
|
| Drug Design | 4 | 2021 | 154 | 1.620 |
Why?
|
| Proto-Oncogene Proteins c-myc | 3 | 2025 | 191 | 1.420 |
Why?
|
| DNA | 8 | 2024 | 1430 | 1.410 |
Why?
|
| Piperazines | 2 | 2022 | 245 | 1.300 |
Why?
|
| Protease Inhibitors | 2 | 2022 | 90 | 0.870 |
Why?
|
| Proteolysis | 1 | 2025 | 177 | 0.850 |
Why?
|
| Pyridines | 2 | 2021 | 242 | 0.830 |
Why?
|
| Molecular Structure | 8 | 2024 | 305 | 0.800 |
Why?
|
| Diamines | 1 | 2022 | 8 | 0.760 |
Why?
|
| Ubiquitin-Protein Ligases | 2 | 2025 | 353 | 0.750 |
Why?
|
| Alkenes | 2 | 2013 | 7 | 0.750 |
Why?
|
| Stereoisomerism | 7 | 2024 | 113 | 0.710 |
Why?
|
| Tudor Domain | 1 | 2021 | 4 | 0.690 |
Why?
|
| CCAAT-Enhancer-Binding Proteins | 1 | 2021 | 39 | 0.680 |
Why?
|
| Chemistry Techniques, Synthetic | 1 | 2020 | 7 | 0.680 |
Why?
|
| Fluorenes | 1 | 2020 | 7 | 0.680 |
Why?
|
| Molecular Probes | 1 | 2020 | 27 | 0.670 |
Why?
|
| Molecular Biology | 1 | 2020 | 69 | 0.650 |
Why?
|
| Peptides | 2 | 2020 | 826 | 0.640 |
Why?
|
| Staining and Labeling | 1 | 2020 | 168 | 0.630 |
Why?
|
| Contraceptive Agents, Male | 3 | 2024 | 31 | 0.560 |
Why?
|
| Antineoplastic Agents | 2 | 2025 | 1751 | 0.560 |
Why?
|
| Protein Kinase Inhibitors | 4 | 2024 | 572 | 0.510 |
Why?
|
| Macrocyclic Compounds | 2 | 2011 | 13 | 0.440 |
Why?
|
| Structure-Activity Relationship | 4 | 2024 | 567 | 0.410 |
Why?
|
| Siloxanes | 1 | 2013 | 2 | 0.400 |
Why?
|
| Hydrocarbons, Halogenated | 1 | 2013 | 5 | 0.400 |
Why?
|
| Triazoles | 3 | 2021 | 130 | 0.390 |
Why?
|
| Molecular Conformation | 3 | 2021 | 94 | 0.370 |
Why?
|
| Luciferases | 3 | 2022 | 126 | 0.360 |
Why?
|
| Aza Compounds | 1 | 2011 | 14 | 0.360 |
Why?
|
| Silanes | 1 | 2011 | 1 | 0.360 |
Why?
|
| Ketones | 1 | 2011 | 25 | 0.360 |
Why?
|
| Hydrocarbons, Aromatic | 1 | 2011 | 5 | 0.350 |
Why?
|
| Nuclear Proteins | 3 | 2022 | 1211 | 0.340 |
Why?
|
| Azepines | 2 | 2021 | 61 | 0.330 |
Why?
|
| Biological Assay | 2 | 2022 | 105 | 0.330 |
Why?
|
| Ligands | 5 | 2022 | 478 | 0.310 |
Why?
|
| Catalysis | 5 | 2020 | 133 | 0.300 |
Why?
|
| Signal Transduction | 6 | 2024 | 4462 | 0.290 |
Why?
|
| Combinatorial Chemistry Techniques | 3 | 2021 | 15 | 0.290 |
Why?
|
| Transcription Factors | 3 | 2022 | 2346 | 0.260 |
Why?
|
| Databases, Factual | 1 | 2011 | 1166 | 0.250 |
Why?
|
| Esters | 2 | 2024 | 33 | 0.240 |
Why?
|
| Hydrocarbons, Chlorinated | 1 | 2005 | 12 | 0.240 |
Why?
|
| Lithium | 1 | 2005 | 66 | 0.240 |
Why?
|
| Pyridones | 1 | 2005 | 124 | 0.220 |
Why?
|
| Activin Receptors, Type I | 1 | 2024 | 33 | 0.220 |
Why?
|
| Neoplasms | 1 | 2019 | 2838 | 0.220 |
Why?
|
| Ubiquitination | 1 | 2025 | 165 | 0.220 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2025 | 232 | 0.210 |
Why?
|
| Microsomes, Liver | 2 | 2023 | 96 | 0.210 |
Why?
|
| Protein Binding | 4 | 2022 | 1672 | 0.210 |
Why?
|
| Morpholines | 1 | 2024 | 60 | 0.210 |
Why?
|
| Enzyme Activation | 2 | 2022 | 582 | 0.210 |
Why?
|
| Contraception | 1 | 2024 | 61 | 0.210 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2023 | 277 | 0.200 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2023 | 47 | 0.200 |
Why?
|
| Neurogenesis | 2 | 2022 | 206 | 0.200 |
Why?
|
| Cell Line, Tumor | 4 | 2025 | 3472 | 0.200 |
Why?
|
| Crystallography, X-Ray | 2 | 2021 | 365 | 0.200 |
Why?
|
| Serotonin and Noradrenaline Reuptake Inhibitors | 1 | 2022 | 14 | 0.200 |
Why?
|
| Cosmic Radiation | 1 | 2022 | 12 | 0.190 |
Why?
|
| Acetic Acid | 1 | 2022 | 17 | 0.190 |
Why?
|
| Gold | 1 | 2022 | 48 | 0.190 |
Why?
|
| Astronauts | 1 | 2022 | 38 | 0.190 |
Why?
|
| Oleic Acid | 1 | 2022 | 15 | 0.190 |
Why?
|
| Radiation Protection | 1 | 2022 | 48 | 0.190 |
Why?
|
| Radiation Exposure | 1 | 2022 | 42 | 0.180 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2023 | 134 | 0.180 |
Why?
|
| Binding Sites | 2 | 2021 | 1193 | 0.180 |
Why?
|
| Space Flight | 1 | 2022 | 98 | 0.170 |
Why?
|
| Humans | 23 | 2025 | 125950 | 0.170 |
Why?
|
| Radiation Injuries | 1 | 2022 | 136 | 0.170 |
Why?
|
| Solutions | 1 | 2020 | 53 | 0.170 |
Why?
|
| Spliceosomes | 1 | 2021 | 47 | 0.170 |
Why?
|
| Histone Code | 1 | 2021 | 45 | 0.170 |
Why?
|
| Genetic Engineering | 1 | 2021 | 159 | 0.170 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2022 | 290 | 0.160 |
Why?
|
| Oligopeptides | 1 | 2020 | 113 | 0.160 |
Why?
|
| Animals | 13 | 2024 | 33185 | 0.160 |
Why?
|
| Immunity | 1 | 2021 | 175 | 0.160 |
Why?
|
| Hippocampus | 2 | 2022 | 772 | 0.160 |
Why?
|
| Cyclization | 3 | 2020 | 17 | 0.160 |
Why?
|
| Luminescent Measurements | 1 | 2019 | 52 | 0.160 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2022 | 313 | 0.160 |
Why?
|
| Models, Molecular | 2 | 2021 | 1065 | 0.160 |
Why?
|
| Immunologic Factors | 1 | 2020 | 181 | 0.150 |
Why?
|
| Virus Replication | 1 | 2021 | 593 | 0.140 |
Why?
|
| Escherichia coli | 2 | 2021 | 968 | 0.140 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2021 | 1597 | 0.140 |
Why?
|
| Drosophila melanogaster | 1 | 2023 | 822 | 0.140 |
Why?
|
| Enzyme Inhibitors | 1 | 2020 | 565 | 0.140 |
Why?
|
| Depressive Disorder, Major | 1 | 2022 | 424 | 0.130 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2019 | 188 | 0.130 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2021 | 267 | 0.130 |
Why?
|
| Histones | 1 | 2021 | 506 | 0.130 |
Why?
|
| Peptide Fragments | 1 | 2021 | 743 | 0.130 |
Why?
|
| Mice | 10 | 2024 | 17590 | 0.130 |
Why?
|
| Cell Cycle Proteins | 1 | 2021 | 657 | 0.130 |
Why?
|
| Antiviral Agents | 1 | 2022 | 777 | 0.130 |
Why?
|
| Carcinogenesis | 1 | 2019 | 341 | 0.120 |
Why?
|
| Cells, Cultured | 1 | 2021 | 2901 | 0.120 |
Why?
|
| Promoter Regions, Genetic | 4 | 2022 | 1211 | 0.120 |
Why?
|
| Metabolomics | 3 | 2023 | 456 | 0.110 |
Why?
|
| Carcinoma, Ductal | 1 | 2013 | 9 | 0.110 |
Why?
|
| Substrate Specificity | 2 | 2011 | 283 | 0.100 |
Why?
|
| Chemistry, Organic | 1 | 2013 | 7 | 0.100 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2023 | 3573 | 0.090 |
Why?
|
| Chromatography, Liquid | 2 | 2023 | 231 | 0.090 |
Why?
|
| Palladium | 1 | 2011 | 15 | 0.090 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2013 | 163 | 0.090 |
Why?
|
| Biological Products | 2 | 2010 | 135 | 0.090 |
Why?
|
| Carbamates | 1 | 2011 | 54 | 0.090 |
Why?
|
| Aldehydes | 1 | 2010 | 28 | 0.080 |
Why?
|
| Gene Library | 2 | 2023 | 212 | 0.080 |
Why?
|
| Tandem Mass Spectrometry | 2 | 2023 | 276 | 0.080 |
Why?
|
| Homeodomain Proteins | 1 | 2013 | 539 | 0.080 |
Why?
|
| Testis | 2 | 2024 | 406 | 0.080 |
Why?
|
| Amino Acids | 2 | 2024 | 614 | 0.080 |
Why?
|
| Trans-Activators | 1 | 2013 | 672 | 0.080 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2010 | 80 | 0.080 |
Why?
|
| Systems Biology | 1 | 2010 | 60 | 0.080 |
Why?
|
| Histone Deacetylases | 1 | 2010 | 113 | 0.080 |
Why?
|
| Ruthenium | 1 | 2009 | 5 | 0.080 |
Why?
|
| Alkynes | 1 | 2009 | 29 | 0.080 |
Why?
|
| Disease | 1 | 2010 | 123 | 0.080 |
Why?
|
| Genes, Reporter | 2 | 2020 | 344 | 0.070 |
Why?
|
| Plasmids | 2 | 2020 | 447 | 0.070 |
Why?
|
| Recombinant Proteins | 2 | 2021 | 1294 | 0.070 |
Why?
|
| High-Throughput Screening Assays | 2 | 2021 | 114 | 0.060 |
Why?
|
| Genetic Vectors | 2 | 2021 | 892 | 0.060 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2013 | 1937 | 0.060 |
Why?
|
| Activin Receptors, Type II | 1 | 2024 | 30 | 0.060 |
Why?
|
| Proteins | 1 | 2010 | 1019 | 0.060 |
Why?
|
| Blood-Testis Barrier | 1 | 2024 | 13 | 0.050 |
Why?
|
| Receptors, Eph Family | 1 | 2024 | 22 | 0.050 |
Why?
|
| Receptor, EphA2 | 1 | 2024 | 28 | 0.050 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2024 | 50 | 0.050 |
Why?
|
| Cytochrome P-450 CYP3A Inhibitors | 1 | 2023 | 10 | 0.050 |
Why?
|
| Bone Morphogenetic Protein Receptors, Type II | 1 | 2023 | 15 | 0.050 |
Why?
|
| Duloxetine Hydrochloride | 1 | 2022 | 14 | 0.050 |
Why?
|
| Central Nervous System Agents | 1 | 2022 | 14 | 0.050 |
Why?
|
| Cytochrome P-450 CYP2D6 | 1 | 2022 | 33 | 0.050 |
Why?
|
| Moon | 1 | 2022 | 13 | 0.050 |
Why?
|
| Cytochrome P-450 CYP1A2 | 1 | 2022 | 49 | 0.050 |
Why?
|
| Luciferases, Firefly | 1 | 2022 | 10 | 0.050 |
Why?
|
| Propranolol | 1 | 2022 | 110 | 0.050 |
Why?
|
| Cluster Analysis | 1 | 2023 | 409 | 0.050 |
Why?
|
| Orphan Nuclear Receptors | 1 | 2022 | 19 | 0.050 |
Why?
|
| Semen | 1 | 2022 | 80 | 0.050 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2022 | 96 | 0.050 |
Why?
|
| Glutathione | 1 | 2023 | 192 | 0.050 |
Why?
|
| Serotonin | 1 | 2022 | 203 | 0.050 |
Why?
|
| Quantitative Structure-Activity Relationship | 1 | 2021 | 15 | 0.040 |
Why?
|
| Protein Conformation, beta-Strand | 1 | 2021 | 14 | 0.040 |
Why?
|
| Endometriosis | 1 | 2024 | 168 | 0.040 |
Why?
|
| Protein Conformation, alpha-Helical | 1 | 2021 | 16 | 0.040 |
Why?
|
| Protein Domains | 1 | 2022 | 245 | 0.040 |
Why?
|
| RNA, Double-Stranded | 1 | 2021 | 59 | 0.040 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2021 | 134 | 0.040 |
Why?
|
| Cell Movement | 1 | 2024 | 845 | 0.040 |
Why?
|
| Molecular Docking Simulation | 1 | 2021 | 131 | 0.040 |
Why?
|
| A549 Cells | 1 | 2020 | 48 | 0.040 |
Why?
|
| Buffers | 1 | 2020 | 28 | 0.040 |
Why?
|
| Gene Amplification | 1 | 2021 | 227 | 0.040 |
Why?
|
| Cytoplasm | 1 | 2021 | 250 | 0.040 |
Why?
|
| Adaptive Immunity | 1 | 2021 | 99 | 0.040 |
Why?
|
| Introns | 1 | 2021 | 283 | 0.040 |
Why?
|
| Cloning, Molecular | 1 | 2021 | 786 | 0.040 |
Why?
|
| Protein Engineering | 1 | 2019 | 61 | 0.040 |
Why?
|
| RNA Splicing | 1 | 2021 | 231 | 0.040 |
Why?
|
| Transfection | 1 | 2020 | 949 | 0.040 |
Why?
|
| Molecular Targeted Therapy | 1 | 2021 | 380 | 0.040 |
Why?
|
| RNA, Small Interfering | 1 | 2019 | 655 | 0.030 |
Why?
|
| Cognition | 1 | 2022 | 782 | 0.030 |
Why?
|
| Male | 4 | 2024 | 62094 | 0.030 |
Why?
|
| Gene Expression | 1 | 2021 | 1489 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2022 | 3705 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2022 | 2390 | 0.030 |
Why?
|
| Apoptosis | 1 | 2021 | 1802 | 0.030 |
Why?
|
| Transcriptional Activation | 1 | 2013 | 415 | 0.020 |
Why?
|
| Female | 3 | 2024 | 67908 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2010 | 149 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2013 | 1490 | 0.020 |
Why?
|
| Drug Delivery Systems | 1 | 2010 | 204 | 0.020 |
Why?
|